Dr. Emmanuel Eni Amadi: The Scientist Pioneering Nanotoxicology and Reshaping Medical Research

From the quiet lab benches of the University of Bradford in West Yorkshire, England, UK, to the most prestigious international stages of nanotechnology, a single scientist is creating a monumental wave of change. Dr. Emmanuel Eni Amadi, PhD, Executive MBA, MSc, PGDip, B.Pharm-a Nanotoxicologist, Medical Researcher, prolific Author, and a UK-based Clinical Pharmacist-is also the visionary CEO/Founder and a dynamic entrepreneur of Amadi Global Leadership Academy | Executive Education, who is fundamentally revolutionising the field of nanotoxicology.
He isn't just a researcher; he's an innovator whose groundbreaking work on Graphene Oxide Nanoparticles and their potential to cause DNA damage in patients with conditions like lung cancer, asthma, and COPD has set a new pace for scientific discovery.
His findings have not only accelerated research but are also actively shaping global safety protocols for nanotechnology. Dr. Amadi's work stands as a testament to how one individual can fundamentally change the trajectory of an entire scientific discipline.
A Methodological Revolution: The Breakthrough That Saved 93% of Research Time:
Every scientist knows the challenge of time-consuming, repetitive work. Dr. Amadi faced this head-on during his doctoral research (2016 - 2019) when he tackled the tedious traditional Comet Assay, a crucial technique for detecting DNA damage, with respect to Graphene Oxide (GO) nanomaterials (NMs) post-exposure to human whole blood and peripheral lymphocytes. This old method required a separate slide for every single blood sample/concentration; analysing a small number of samples was a multi-week ordeal.
In a landmark innovation, Dr. Amadi optimised the Medium Throughput Alkaline Comet Assay, leading to his own branded comet assay method that has transformed the pace of research: The Amadi ProtocolTM or The Amadi Comet Assay ProtocolTM: An Optimised, Highly-Sensitive Medium Throughput Comet Assay for DNA Damage Assessment.
During his doctoral research at the University of Bradford, West Yorkshire, England, United Kingdom, in 2018, he was the first to introduce the Medium Throughput Comet Assay to the University of Bradford Toxicology Lab. of Professor Diana Anderson. Under the UK National Health Service (NHS) and around the world, Dr. Amadi was the first to investigate the genotoxic effects of commercially available graphene oxide (GO) nanomaterials (NMs) GO (15-20 sheets; 4-10% edge-oxidized; 1 mg/ml) in vitro, specifically, the DNA damage impacts and other genotoxic endpoints in human whole blood and peripheral blood leucocytes (PBL) from healthy individuals from Manchester and Bradford city, England and real-life patients diagnosed with chronic pulmonary diseases, i.e., asthma, chronic obstructive pulmonary disease (COPD), and lung cancer recruited from the ambulatory clinic of Professor Badie Jacob's Respiratory Clinic, Bradford Royal Infirmary (BRI) and Dr Abid Aziz, a Respiratory Consultant at St Luke's Hospital, Bradford, West Yorkshire, UK (2016-2019).
By the conclusion of his PhD in 2019, Dr Amadi had already refined and optimised the classical Comet Assay methodology in four core areas, resulting in a significantly improved technique. The classical decade-old Comet Assay, originally developed to detect DNA strand breaks at the single-cell level, suffers from several limitations:
1.High resource demands.
2.Experimental variability.
3.Unrealistic exposure durations.
4.Insensitivity to subtle DNA lesions.
5.Suboptimal electrophoresis conditions.
Through systematic refinement, Dr. Amadi addressed each of these weaknesses and transformed the assay into a more sensitive, ecologically and economically relevant method. The Amadi ProtocolTM is now suitable for translational studies in nanotoxicology and cancer research and has been recognised by independent experts, adopted by international laboratories, and is on track to become a new industry standard.
This new method allows for the simultaneous analysis of 12 samples on a single slide, compressing a two-week process into a single day. This extraordinary 93%-time savings is more than just a convenience; it allows for higher-volume experiments and significantly accelerates the pace of scientific discovery.
The impact of this innovation is clear. Experts at leading research institutions across the United Kingdom and Europe have adopted the Amadi Comet Assay ProtocolTM in their own laboratories.
Recognised for Excellence: An International "Best Paper Award"
Dr. Amadi's preeminent standing in the field was recently cemented by the prestigious "Best Paper Award" he received in September 2024 from the International Journal of Health and Clinical Research (IJHCR) - Netherlands. This distinguished honour is granted to just one paper annually from a highly competitive pool of international submissions.
The award recognised his research paper titled: "Graphene Oxide Nanoparticles: A Genotoxic Risk for Patients with Lung Cancer, COPD and Asthma," praising it for its "outstanding and original contributions" and calling its findings "a significant advancement with a demonstrable impact on the future of health and clinical research."
From the Lab to the Lectern: A Global Voice in Science
Dr Emmanuel Eni Amadi has been recognised internationally for his pioneering nanotoxicology research, having delivered invited oral presentations at leading global conferences including the NanoBoston World Conference in Boston, Massachusett, USA (2019), the InterNano Conference at the University of Silesia in Katowice, Poland (2019), and multiple UK-based nanotechnology symposia; his postdoctoral interview presentation at the Skaggs Building, University of Montana, Missoula, Montana (2019) was subsequently published in the University of Bradford's Bradford ChemBio Newsletter (2019). His work has been widely cited by researchers in the field of nanotoxicology and featured in academic textbooks, including "Nanotechnology in Wound Healing" (2025, CRC Press). These invitations highlight his international standing and the high regard in which the global scientific community holds his work.
His research skills are extensive and include a wide array of specialised techniques:
1.Pioneering Human Samples: He was the first globally to use human whole blood samples from real patients in a clinical setting for genotoxicity studies with Graphene Oxide nanomaterials, bridging a critical gap between lab work and translational medicine.
2.Nanoparticle Characterisation: Utilising advanced techniques like Dynamic Light Scattering (DLS) and Zeta potential.
3.Molecular & Genetic Analysis: The extraction and isolation of proteins, followed by DNA and RNA, from human blood and cells. This is followed by the analysis of gene expression and the synthesis of complementary DNA (cDNA). The resulting cDNA is then used for gene identification, cloning, and sequencing. These techniques are foundational for creating cDNA libraries and are applied in developing personalised medicines and vaccines.
4.Advanced Microscopy & Assays: Expertise in techniques such as Confocal Microscopy (TIRF), Flow Cytometry, Comet Assay, Micronucleus Assay, Polymerase Chain Reaction (PCR), Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR), and Western Blot.
The Future of Nanotoxicology is Here:
Dr. Emmanuel Eni Amadi's work exemplifies the powerful combination of innovation and expertise. By not only generating groundbreaking findings but also creating the tools for others to follow, he has proven himself to be a preeminent leader in his field. His contributions are not just a part of the scientific conversation-they are helping to shape it.
LinkedIn: https://www.linkedin.com/in/DRee-amadi/
Leadership Profile: https://www.amadiglobal.co.uk/dr-emmanuel-eni-amadi

Amadi Global Leadership Academy | Executive Education
Company No: SC775532
Dr Emmanuel Eni Amadi
info@amadiglobal.co.uk
+44 0743-264-8431

The Amadi GlobalTM is a parent Corporate Conglomerate with a series of firms based in the City of Glasgow, Scotland, United Kingdom.
Established in Nov. 2019, We focus on Four Core Business Areas.
1. Public Speaking
2. Pharmacy Business and Consultancy
3. Amadi Global Publishing Book Club
4. Leadership Academy/ Executive Eduaction

This release was published on openPR.